CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is a protein that plays a crucial role in regulating immune responses, particularly in T-cell activation and proliferation. The specific substance you mentioned is a fusion protein that combines the extracellular domain of human CTLA-4 with the Fc domain of human immunoglobulin G1 (IgG1). This design enhances the stability and half-life of the protein in circulation, allowing for prolonged therapeutic effects. The presence of disulfide bonds in the bimolecular structure contributes to its structural integrity and functional efficacy. This fusion protein is primarily utilized in immunotherapy, particularly in cancer treatment, as it can modulate immune responses by blocking the interaction between CTLA-4 and its ligands, thereby promoting T-cell activation. The CAS number 706808-37-9 identifies this specific compound, which is part of a broader class of biologics aimed at enhancing anti-tumor immunity. Overall, this fusion protein exemplifies the innovative approaches in biopharmaceutical development targeting immune checkpoints.

CTLA-4 (antigen)[29-tyrosine,104-glutamic acid] (human extracellular domain-containingfragment) fusion protein with immunoglobulin G1 (human monoclonal Fcdomain-containing fragment), bimol. (120®120')-disulfide (9CI)

706808-37-9: CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) is a protein that plays a crucial role in regulating immune responses, particularly in T-cell activation and proliferation. The specific substance you mentioned is a fusion protein that combines the extracellular domain of human CTLA-4 with the Fc domain of human immunoglobulin G1 (IgG1). This design enhances the stability and half-life of the protein in circulation, allowing for prolonged therapeutic effects. The presence of disulfide bonds in the bimolecular structure contributes to its structural integrity and functional efficacy. This fusion protein is primarily utilized in immunotherapy, particularly in cancer treatment, as it can modulate immune responses by blocking the interaction between CTLA-4 and its ligands, thereby promoting T-cell activation. The CAS number 706808-37-9 identifies this specific compound, which is part of a broader class of biologics aimed at enhancing anti-tumor immunity. Overall, this fusion protein exemplifies the innovative approaches in biopharmaceutical development targeting immune checkpoints.

Belatacept (BMS 224818), a T-cell costimulation inhibitor, targets CD80/86 for transplant immunosuppression.

CAS 706808-37-9

CTLA-4 (antigen)[29-tyrosine,104-glutamic acid] (human extracellular domain-containingfragment) fusion protein with immunoglobulin G1 (human monoclonal Fcdomain-containing fragment), bimol. (120®120')-disulfide (9CI)

Belatacept

Ref: TM-T64239